OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant
Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.
You may also be interested in...
Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.
Sanofi benefits from coronavirus-triggered stockpiling in Q1, with Consumer Healthcare head Alan Main suggesting the pandemic may have turned more consumers into regular dietary supplement users
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.